Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Standardized Research E-cigarette (SREC)

Phase 1Small molecule

MMasonic Cancer Center, University of Minnesota

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smoking CigaretteActive, not recruiting

Smoking CigarettePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Smoking Cigarette

NCT04003805

Clinical

Trials by Indication[1]

Smoking Cigarette1 trial

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT04003805·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standardized Research E-cigarette (SREC). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standardized Research E-cigarette (SREC) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standardized Research E-cigarette (SREC). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMasonic Cancer Center, University of Minnesota

Related News